Market Overview
Size, scope, and demand anchors
- Brevintel analysis values the market at USD 8.4 billion in 2025 ($8.4B) and projects USD 21.4 billion by 2035 at a 9.8% CAGR during 2026–2035.
- Headline cards also retain $7.1B and 10.9% from the source scrape alongside the narrative USD 21.4 billion outlook.
- Historic spend rose at a 9.0% CAGR from USD 6.5 billion in 2022 to USD 7.1 billion in 2023, USD 7.7 billion in 2024, and USD 8.4 billion in 2025.
- Coverage captures outsourced regulatory consulting, product testing and analysis, labeling and health-claims review, GMP/HACCP quality management, market-authorization submissions, and post-market surveillance.
- Buyers include dietary supplement manufacturers, functional food and nutraceutical companies, sports nutrition brands, infant formula producers, contract manufacturers, distributors, importers, and exporters.
- SGS SA led with over 12.2% share in 2025; SGS SA, Intertek Group PLC, Eurofins Scientific SE, NSF International, and Bureau Veritas SA held 43.5%.
- Product Testing & Analysis led services at USD 2.5 billion (29.9%) and is the fastest major service segment at 10.9% CAGR.
- North America led regions at USD 3.3 billion (38.8%); Asia Pacific is the fastest region at a 12.2% CAGR.
Compliance perimeter and jurisdictional anchors
- Many compliance activities are conditions of market access rather than discretionary operating improvements.
- In the United States, 21 CFR Part 111 requires specifications for identity, purity, strength, and composition and appropriate testing before product release.
- FSMA Foreign Supplier Verification Program extends accountability to importers, while warning letters and inspections expose supplier-verification gaps.
- The January 2025 decision to revoke authorization for Red No. 3 in food and ingested drugs, including dietary supplements, created reformulation, label-review, and retesting work ahead of the January 2027 deadline.
- EFSA assessed 292 novel food applications between 2018 and 2024, while updated scientific guidance applicable from February 2025 raised evidentiary requirements.
- India’s re-operationalized nutraceutical rules and China’s health-food filing system expand registration and market-entry demand across Asia Pacific.
- Providers that link testing results, regulatory interpretation, and jurisdiction-specific submissions are better positioned than firms competing only on assay capacity.
- Internal regulatory payroll, ingredient procurement, manufacturing capital expenditure, and pharmaceutical drug-regulatory services are excluded from the addressable market.
Market Dynamics
Drivers
- U.S. Part 111 finished-batch controls convert statutory obligations into recurring laboratory demand for identity, purity, strength, and composition.
- FSVP adds importer buyers that must verify foreign suppliers meet applicable U.S. safety requirements across multi-country supply chains.
- EU novel food and health-claim pathways depend on scientific evidence, product characterization, toxicology, and dossier quality.
- EFSA’s revised novel food guidance effective from February 2025 raises the value of well-structured evidence packages at submission.
- Asia Pacific formalization in India and China expands domestic compliance while export-oriented manufacturers reconcile origin and destination rules.
- A single product launch can require several service categories, raising outsourcing intensity even where manufacturer counts grow more slowly.
Restraints and structural constraints
- Outsourced compliance is more affordable for established manufacturers with broad portfolios than for micro-brands with limited SKUs.
- Smaller firms may purchase services only at market entry, retailer request, inspection findings, or import disruption.
- Novel food dossiers, health-claim substantiation, and concurrent filings across FDA, EFSA, FSSAI, and Chinese authorities require scarce specialist talent.
- Capacity constraints can lengthen project timelines and limit boutique providers’ ability to scale into new geographies.
- Automation can organize evidence and tracking but cannot replace jurisdiction-specific scientific and legal interpretation.
- Mandatory requirements protect demand from cyclical softness, yet purchasing friction still delays conversion among cost-sensitive brands.
Segmentation Analysis
By service type
- Product Testing & Analysis is the largest service category at USD 2.5 billion, or 29.9%, of 2025 revenue and the fastest major service segment at 10.9% CAGR.
- Its position reflects recurring release testing, contaminant screening, identity verification, and analytical support under dietary supplement cGMP expectations.
- Quality Management System (GMP/HACCP) services represented USD 1.7 billion in 2025 through audit, gap-assessment, corrective-action, and re-certification work.
- Regulatory Consulting & Advisory Services generated USD 1.5 billion in 2025, while Labeling & Health Claims Compliance contributed USD 1.2 billion.
- Market Authorization & Regulatory Submission Services totaled USD 0.8 billion and are projected to expand at 10.6% CAGR as novel food and cross-border filings broaden.
- Post-Market Surveillance & Compliance Monitoring Services represented USD 0.7 billion and are projected to grow at 10.8% CAGR on marketplace verification needs.
- Advisory work concentrates where classification and submission strategy are uncertain; labeling work tracks SKU launches, reformulations, and claims revisions.
- Segment growth favors services that must be repeated, verified, or maintained after a product reaches market.
By product type
- Dietary supplements are the largest product category at USD 3.4 billion, or 40.5%, of 2025 revenue, combining repeat testing, manufacturing controls, and label review.
- Functional foods and nutraceuticals accounted for USD 2.5 billion in 2025, reinforced by classification questions near food, supplement, novel food, or drug-like boundaries.
- Sports nutrition is the fastest-growing product segment at 11.8% CAGR, shaped by reputational risk as well as statutory requirements.
- NSF Certified for Sport screens for more than 295 banned substances and is recognized by USADA, MLB, NHL, and CFL.
- Infant and pediatric nutrition remains smaller but high-intensity because compositional safety, claims, and labeling carry greater scrutiny.
- Other categories, including herbal products, enzymes, and emerging functional ingredients, grow more slowly amid fragmented pathways by jurisdiction.
By end user
- Manufacturers & brand owners are the largest end-user group at USD 4.7 billion, or 56.3%, of 2025 revenue across the product lifecycle.
- Contract manufacturers/CMOs accounted for USD 2.0 billion in 2025 and are expected to expand at 11.1% CAGR while serving multiple brand-owner clients.
- Distributors & retailers represented USD 1.0 billion in 2025; Amazon dietary supplement policy has raised third-party verification relevance in e-commerce.
- Importers & exporters represented USD 0.7 billion, supported by U.S. FSVP obligations and Chinese market-entry registration requirements.
- CMOs favor providers that combine site audit support with client-specific labeling, testing, and documentation programs.
- For distributors and trade intermediaries, the service need centers on supply-chain assurance and documentation rather than formulation development.
Regional Outlook
North America and Europe
- North America was the largest regional market in 2025 at USD 3.3 billion, or 38.8% of global revenue, and is projected to expand at an 8.7% CAGR through 2035.
- The United States anchors demand through its large supplement manufacturing and import base, Part 111 controls, and FSVP obligations.
- Comparatively lower regional growth reflects maturity: incremental spend follows enforcement, reformulation, new products, and supply-chain changes.
- Canada adds a natural-health-product pathway that raises the value of cross-border regulatory support for dual-market suppliers.
- Europe represented USD 2.4 billion, or 28.5%, of global revenue in 2025 and is projected to grow at a 9.2% CAGR.
- Demand concentrates in Germany, the UK, France, Italy, and Spain, where novel food and health-claim substantiation drive higher-value dossier work.
- Post-Brexit compliance requires parallel management of classification, claims, evidence, and authorization for EU and UK portfolios.
- EFSA’s 292-application novel-food cohort and strengthened 2025 guidance reinforce specialist dossier development and analytical characterization.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific accounted for USD 1.8 billion, or 21.6%, of global revenue in 2025 and is projected to reach USD 5.8 billion by 2035 at a 12.2% CAGR.
- China’s health-food filing structure and oversight of imported functional ingredients increase registration and import-compliance demand.
- India’s nutraceutical rules create demand across product registration, GMP implementation, and health-claim controls.
- Export-oriented manufacturers in China, India, South Korea, Japan, and Australia must reconcile origin-market rules with U.S. or European requirements.
- Latin America represented approximately 7% of global revenue in 2025 and is projected to grow at a 9.8% CAGR, led by Brazil, Mexico, and Argentina.
- Middle East & Africa represented approximately 4% of global revenue in 2025 and is projected to expand at a 9.8% CAGR.
- Saudi Arabia and the UAE are principal commercial centers; halal verification adds ingredient-level review alongside conventional compliance.
- South Africa adds specialized demand through its framework for complementary medicines closer to trade-channel market entry.
Competitive Landscape
Structure and recent developments
- The market remains fragmented despite scale advantages held by major testing, inspection, and certification groups.
- SGS SA leads with an estimated 12.2% share; the top five companies collectively account for 43.5% of 2025 revenue.
- SGS expanded North American capacity in 2025 through RTI Laboratories and Murray-Brown Laboratories acquisitions supporting food-safety and nutraceutical testing.
- Intertek acquired Costa Rican food-safety and medical-device testing provider Suplilab in November 2025, extending its Central American footprint.
- Eurofins completed 40 acquisitions during 2025 and reported double-digit Food & Feed Testing growth in Asia Pacific.
- NSF International holds a defensible position via Certified for Sport and accepted-certification status under Amazon’s supplement policy.
- Bureau Veritas agreed to divest its worldwide food-testing business to Mérieux NutriSciences for an enterprise value of EUR 360 million, covering 34 laboratories and about 1,900 staff across 15 countries.
- Updated EFSA novel food guidance applicable from February 2025 increased the importance of robust safety and toxicological documentation in new dossiers.
Integrated producers
- SGS SA
- Intertek Group PLC
- Eurofins Scientific SE
- NSF International
- Bureau Veritas SA
- Mérieux NutriSciences
Specialty suppliers
- EAS Consulting Group
- Burdock Group & Associates
- Freyr Solutions
- RSI
- SCS Consulting Services
- FoodChain ID
- Orionex Regulatory Solutions
- Fiducia Globus
- Cosmereg
- Citron Regulatory Compliance Corp.